Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ENOC
1151
DELISTED
EnerNOC, Inc.
ENOC
| $12.1M | 0.02% |
1,558,588
+296,388
| +23% | +$1.74M |
|
1152
Utah Medical Products
UTMD
$230M
| $12.1M | 0.02% |
166,545
+21,845
| +15% | +$1.44M |
|
|
BMS
1153
DELISTED
Bemis
BMS
| $12.1M | 0.02% |
260,600
-96,000
| -27% | -$4.42M |
|
|
EQM
1154
DELISTED
EQM Midstream Partners, LP
EQM
| $12M | 0.02% |
161,452
+69,902
| +76% | +$5.23M |
|
1155
United States Lime & Minerals
USLM
$3.42B
| $12M | 0.02% |
767,500
+87,500
| +13% | +$1.37M |
|
|
SWFT
1156
DELISTED
Swift Transportation Company
SWFT
| $12M | 0.02% |
453,500
-1,418,400
| -76% | -$34.2M |
|
|
MSFG
1157
DELISTED
MainSource Financial Group Inc
MSFG
| $12M | 0.02% |
358,600
+34,200
| +11% | +$1.13M |
|
1158
Dr. Reddy's Laboratories
RDY
$10.3B
| $12M | 0.02% |
1,423,500
+872,385
| +158% | +$7.09M |
|
|
SIGM
1159
DELISTED
Sigma Designs Inc
SIGM
| $12M | 0.02% |
2,047,900
+154,700
| +8% | +$937K |
|
1160
Radware
RDWR
$1.25B
| $12M | 0.02% |
682,495
+201,598
| +42% | +$3.42M |
|
|
NTL
1161
DELISTED
Nortel Invesora 1/20 Ser B Shr
NTL
| $12M | 0.02% |
383,000
-15,900
| -4% | -$456K |
|
1162
Artivion
AORT
$1.39B
| $12M | 0.02% |
599,300
+51,400
| +9% | +$921K |
|
|
FFIC
1163
DELISTED
Flushing Financial
FFIC
| $12M | 0.02% |
424,100
+4,000
| +1% | +$112K |
|
|
JE
1164
DELISTED
Just Energy Group Inc
JE
| $12M | 0.02% |
69,136
+3,569
| +5% | +$673K |
|
1165
Cousins Properties
CUZ
$4.93B
| $11.9M | 0.02% |
+339,693
| New | +$11.7M |
|
1166
Unum
UNM
$14.7B
| $11.9M | 0.02% |
+256,000
| New | +$11.8M |
|
|
HR
1167
DELISTED
Healthcare Realty Trust Incorporated
HR
| $11.9M | 0.02% |
349,400
+232,500
| +199% | +$7.82M |
|
1168
Chegg
CHGG
$89.3M
| $11.9M | 0.02% |
969,400
+59,500
| +7% | +$647K |
|
1169
Lowe's Companies
LOW
$122B
| $11.9M | 0.02% |
+153,500
| New | +$12.5M |
|
1170
Ironwood Pharmaceuticals
IRWD
$674M
| $11.9M | 0.02% |
752,522
+529,897
| +238% | +$7.7M |
|
1171
Nathan's Famous
NATH
$397M
| $11.9M | 0.02% |
188,800
+20,900
| +12% | +$1.36M |
|
1172
Enpro
NPO
$7.12B
| $11.9M | 0.02% |
166,200
+21,900
| +15% | +$1.52M |
|
1173
Red Rock Resorts
RRR
$3.73B
| $11.8M | 0.02% |
502,700
+350,900
| +231% | +$8.18M |
|
1174
Willis Lease Finance
WLFC
$1.21B
| $11.8M | 0.02% |
1,327,200
-3,600
| -0.3% | -$29.8K |
|
1175
Neogen
NEOG
$2.59B
| $11.8M | 0.02% |
456,000
-267
| -0.1% | -$6.39K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.